VEGF Plasmid Gene Therapy for Microcirculation & Hair Loss

What VEGF Plasmid Gene Therapy Is—In One Minute

VEGF plasmid gene therapy uses a small, circular piece of DNA (called a plasmid) that gives your cells a short-term nudge to produce VEGF—the body's master signal to grow tiny new blood vessels.

Think of VEGF as instructional DNA circles that temporarily boost your body's natural ability to create better circulation where you need it most.

The simple equation

More micro-vessels → better local circulation → potential improvements in oxygen delivery, nutrients, and tissue resilience.

Here's what makes this approach unique: the plasmids don't integrate into your genes or change your DNA. They stay in the cell nucleus temporarily, deliver their instructions to make VEGF protein, and then naturally degrade. Your original DNA remains completely unchanged.

This process triggers angiogenesis—the formation of new blood vessels—in the specific areas where the therapy is administered. These new micro-vessels create additional pathways for oxygen and nutrients to reach tissues while improving waste removal.

Why Blood Flow and Microcirculation Matter More Than You Think

Your circulatory system is like a highway network, but the real magic happens in the smallest streets—your capillaries and micro-vessels. These tiny blood vessels are where the actual exchange of oxygen, nutrients, and waste occurs at the cellular level.

Microcirculation underpins nearly everything

physical performance, recovery speed, skin and scalp health, cognitive function, and healthy aging. When microcirculation declines, tissues don't get what they need to function optimally.

The aging reality

Capillary density and VEGF signaling naturally decline with age. This affects muscle performance, skin quality, hair follicle health, wound healing, and overall tissue resilience. By age 65, many people have 20-30% fewer functional capillaries in their muscles compared to their younger years.

Poor microcirculation contributes to

Reduced exercise capacity and slower recovery

Thinning hair and compromised scalp health

Slower wound healing and tissue repair

Decreased cognitive performance

Age-related muscle weakness (sarcopenia)

Compromised skin health and appearance

Compromised blood and oxygen circulation

VEGF plasmid gene therapy works by temporarily boosting the body's natural vessel-building signals in targeted areas, potentially restoring some of the microcirculatory capacity that diminishes over time.

What People Use VEGF Plasmid Gene Therapy For

At Longevity Advanced, patients seek VEGF plasmid gene therapy for three primary applications:

Hair Rejuvenation

Hair follicles require a robust blood supply to maintain healthy growth cycles. VEGF therapy may improve scalp microcirculation, supporting better nutrient delivery to follicles and potentially encouraging thicker, fuller-looking hair over time.

Vascularization (Microcirculation)

For those seeking to support local circulation in areas with compromised blood flow—whether due to aging, diabetes-related issues, lower leg ischemia, or other circulation challenges. This includes wound healing support and general microcirculatory enhancement.

Sarcopenia & Performance

Adults experiencing age-related muscle decline or athletes seeking enhanced endurance and recovery. Better muscle oxygenation through improved capillary density may support strength, reduce fatigue, and accelerate recovery.

Sarcopenia & Performance

What the Clinical Evidence Shows

The strongest evidence base for VEGF plasmid gene therapy comes from extensive research in peripheral artery disease (PAD), where circulation problems are severe and measurable improvements are clinically significant.

Proven Outcomes in Circulation Research

Studies in PAD patients demonstrate that VEGF plasmid therapy can produce:

Improved angiography results showing new vessel formation

Enhanced ankle-brachial index (ABI) indicating better leg circulation

Increased tissue oxygenation measured through TcPO₂ testing

Extended walking distances with notable improvements in pain-free walking

Sustained benefits lasting 3-5 years after treatment

In one landmark study, patients with severe circulation issues experienced up to 683% improvement in walking distance, with benefits maintained over multiple years.

Broader Applications

While the core evidence comes from PAD research, the biological mechanisms of improved microcirculation may translate to other applications. For hair, muscle performance, and general vascularization, we use careful "may" language because research in these areas is ongoing, though the underlying science of VEGF-mediated angiogenesis is well-established.

Exceptional Safety Profile

VEGF plasmid gene therapy (Neovasculgen) has one of the most comprehensive safety databases among gene therapies:

Over 10,000 patients treated with extensive post-marketing surveillance

Non-integrating plasmids that don't alter your DNA

5-year follow-up data showing no increased cancer risk

Local injection approach that didn't raise systemic VEGF levels in trials

Mild side effects only - temporary local reactions at injection sites

This safety record spans over a decade of clinical use, establishing VEGF plasmid therapy as one of the safest gene therapy approaches available.

What to Expect: Timeline and Journey

Realistic Timeline Expectations

VEGF plasmid gene therapy works by triggering your body's natural vessel-building processes, so effects develop gradually as new micro-vessels form and mature.

For hair applications

Visible improvements are often discussed around the 6-month mark, as hair growth cycles are naturally slow.

For microcirculation and performance

Benefits may be noticed sooner in some individuals, though peak effects typically develop over several months.

Durability

Based on circulation research, effects can last 3-5 years, making this a long-term solution rather than ongoing maintenance therapy.

Clinical Development

This protocol was developed by Dr. William Halford, a virologist who dedicated his career to HSV research and spent years refining the immunotherapy approach.

Since 2011, the treatment has been administered to hundreds of patients, with continuous refinement based on clinical outcomes and patient response patterns.The protocol does not eradicate the virus—HSV remains in the dorsal root ganglia permanently. Instead, it trains the immune system to maintain the virus in a deeply suppressed latent state, reducing or eliminating both outbreak frequency and the neurological symptoms associated with viral reactivation.

Clinical Development

This protocol was developed by Dr. William Halford, a virologist who dedicated his career to HSV research and spent years refining the immunotherapy approach.

Your Treatment Journey

Phase 1

Initial consultation

Assess candidacy and discuss goals

Phase 2

Eligibility screening

Personalized evaluation of suitability

Phase 3

Treatment visit

Targeted injections administered over 1-2 days

Phase 3

Treatment visit

Targeted injections administered over 1-2 days

Phase 4

Follow-up monitoring

Track progress and optimize outcomes

Important Note on Individual Variation

The specific protocol varies by application and individual needs. Some patients may benefit from a second round of injections for enhanced effectiveness.

Individual results vary, and consistency with healthy lifestyle habits supports optimal outcomes.

Who May Be a Candidate for VEGF Plasmid Gene Therapy

VEGF plasmid gene therapy may be suitable for adults seeking non-surgical options to support local blood flow and microcirculation.

Common candidate profiles include:

Hair Concerns

Individuals experiencing early to moderate hair thinning

Those frustrated with limited results from conventional treatments

People seeking a long-term, non-daily maintenance approach

Circulation and Performance

Adults noticing age-related decline in strength or endurance not explained by training alone

Individuals with circulation challenges affecting specific areas

Those seeking to optimize muscle oxygenation for performance or recovery

General Vascularization Support

People interested in supporting tissue health through improved microcirculation

Individuals with slow-healing areas or compromised local blood flow

Those pursuing proactive approaches to age-related vascular decline

Personalized screening is essential

this therapy isn't suitable for everyone. Factors like medical history, current health status, and specific goals all influence candidacy. A thorough consultation determines whether VEGF plasmid gene therapy aligns with your individual situation and objectives.

Safety, Oversight, and Regulatory Status

Treatment Oversight

VEGF plasmid gene therapy is not approved by the U.S. FDA. Treatment is provided outside the United States at Longevity Advanced locations in Roatán and the Bahamas, where protocols are reviewed by an IRB (Institutional Review Board), if applicable.

Safety Reassurance

The non-integrating nature of plasmid therapy means your DNA remains unchanged. The plasmids work temporarily in cell nuclei before naturally degrading, leaving no permanent genetic modifications.

An estimated 10,000 patients have been treated in Russia for more than a decade with no severe adverse events. The most common complaint was pain at the injection sites.

Extensive 5-year follow-up data confirms no increased cancer risk, and local injection approaches used in clinical trials did not elevate systemic VEGF levels. Most patients experience only mild, temporary local reactions at injection sites.

This robust safety profile, combined with over a decade of clinical use, establishes VEGF plasmid gene therapy among the safest approaches in the gene therapy field.

FREQUENTLY ASKED QUESTIONS

How does VEGF gene therapy work?

Neovasculgen® delivers the VEGF gene to target tissues via a plasmid. This gene encourages cells to produce VEGF protein, promoting angiogenesis, and improving local oxygenation.

What conditions can VEGF gene therapy treat?

VEGF gene therapy is used for PAD. However, its physiological effects also support wound healing, muscle oxygenation, neuroprotection, hair follicle blood supply, and tissue regeneration.

Is the treatment safe?

Yes, clinical trials have demonstrated that Neovasculgen® is safe, with no systemic side effects. It has been on the market for over 12 years with proven long-term safety and efficacy.

What benefits can I expect from this treatment?

PAD patients experience increased pain-free walking distances, improved local blood supply, and a higher Ankle-Brachial Index (ABI), which indicates better blood circulation in the legs. The effects on improving endurance and hair condition in healthy adults are under investigation.

How many patients have received this therapy?

More than 10,000 patients have successfully received VEGF gene therapy.

How is the therapy administered?

The treatment is delivered locally via a set of intramuscular injections, usually over ten. For hair rejuvenation, the injections resemble a PRP treatment (over 30 injections).

Who should consider VEGF gene therapy?

PAD patients and patients with diminished blood supply to the legs (e.g. due to diabetes type 2 or sarcopenia);

If you experience early symptoms of age-related deterioration of hair quality.

If you are looking for ways to enhance the performance of key muscles.

Are there any side effects?

Only pain at the injection site due to the additional components in the drug that facilitate the entrance of plasmids into the cells. No other side effects have been observed in clinical trials or reported in practice.

Can I do VEGF therapy If I'm a competitive athlete?

All gene therapies, including VEGF, are banned by WADA.

How long does the effect last?

Studies in PAD patients showed a lasting effect for up to 5 years. We recommend reinjecting in 3 years to maintain the maximum effect.

Why does the VEGF therapy have only local effect?

VEGF protein predominantly remains localized because it strongly binds to the extracellular matrix and primarily influences the immediate surrounding cells, especially endothelial cells. Its rapid uptake by cells through receptors, combined with its short half-life (approximately 30 minutes), restricts it from circulating widely, keeping it concentrated near the area of production.

Why can’t you measure VEGF levels in blood?

The localized nature of VEGF means the accurate measurement of its expression requires direct tissue biopsies from the specific region of interest. However, monitoring VEGF expression effectively over time or across multiple areas would demand multiple invasive procedures. Since repeated biopsies of healthy tissues raise ethical issues and patient discomfort, direct measurement through biopsies isn't standard practice for healthy tissues.

How can you be sure VEGF plasmid gets expressed in the cells?

Data from Neovasculgen plasmid studies confirm active VEGF expression, with in vitro results showing VEGF protein levels increasing significantly from baseline (~11-27 pg/ml) to approximately 151 pg/ml within 96 hours after transfection. Additionally, preclinical mouse studies using a hind-limb ischemia model demonstrated a substantial increase in blood flow restoration, achieving up to 80-90% recovery at 35 days post-treatment, highlighting effective, sustained VEGF expression and therapeutic benefit.

VEGF Plasmid Gene Therapy

What VEGF Plasmid Gene Therapy Is—In One Minute

What People Use VEGF Plasmid Gene Therapy For

Hair Rejuvenation

Vascularization (Microcirculation)

Sarcopenia & Performance

Sarcopenia & Performance

Your Treatment Journey

Initial consultation

Eligibility screening

Treatment visit

Treatment visit

Follow-up monitoring

Safety Reassurance

Take the Next Step

Ready to explore whether VEGF plasmid gene therapy could benefit you?

Want to learn more about specific applications?

Treatments

Resource & Media

Treatments

Resource & Media